Evaluation bone uptake of alendronate sodium via vaginal route by gamma scintigraphy, Vaginal uptake of alendronate sodium

Journal of Drug Delivery Science and Technology

Volumn 24, Issue 2, 2014, Pages 218-221

  Ilem Ozdemir, D ^a   Asikoglu, M ^a   Guneri, T ^a   Koseoglu, K ^a   Ozkilic, H ^a  

^a EGE UNIVERSITY   (Turkey)

Author keywords

Alendronate sodium; Bone uptake; Gamma scintigraphy; Intravaginal application; Technetium 99m

Indexed keywords

ALENDRONIC ACID; ALENDRONIC ACID TC 99M; ASCORBIC ACID; STANNOUS CHLORIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BONE; BONE UPTAKE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG UPTAKE; FEMALE; GAMMA CAMERA; GAMMA SCINTIGRAPHY; ISOTOPE LABELING; KIDNEY; LIVER; NONHUMAN; RABBIT; RADIO THIN LAYER CHROMATOGRAPHY; RADIOCHEMISTRY; THIN LAYER CHROMATOGRAPHY;

EID: 84899555226     PISSN: 17732247     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1773-2247(14)50035-4     Document Type: Article

References (25)

1. Bartl R., Frisch B., Von Tresckow E., Bartl C. - Bisphosphonates in Medical Practice. - Spriger-Verlag, Heidelberg, 2007, p. 35-70.
2. Sparidans R.W., den Hartigh J. - Chromatographic analysis of bisphosphonates. - Pharm World Sci., 1, 21, 1-21, 1999.
3. Chaiamnuay S., Saag K.G. - Postmenopausal osteoporosis. What have we learned since the introduction of bisphosphonates? - Reviews in Endocrine and Metabolic Disorders, 7, 101-112, 2006. (Pubitemid 46049522)
4. Fleisch H. - Development of bisphosphonates. - Breast Cancer Res., 4, 30-34, 2002.
5. Ayranov M., Strezov A., Jordanova E., Piperkova E., Sergieva S. - Quality control and clinical application of two bone imaging 99mTc radiopharmaceuticals. - Journal of Radioanalytical and Nuclear Chemistry, 240, 349-352, 1999. (Pubitemid 29202333)
6. Sambrook PN., Rodriguez JP., Wasnich RD., Luckey MM., Kaur A., Meng L., Lombardi A. - Alendronate in the prevention of osteoporosis: 7-year follow-up. - Osteoporos Int., 15 (6), 483-488, 2004. (Pubitemid 38843177)
7. Biswas P., Wilton L., Shakir S. - Pharmacovigilance study of alendronate in England. - Osteoporosis International, 14, 507-514, 2003.
8. Porras AG., Holland SD., Gertz BJ. - Pharmacokinetics of alendronate. - Clin. Pharmacokinet., 36 (5), 315-328, 1999.
9. Gertz BJ., Holland SD., Kline WF., Matuszewski BK., Freeman A., Quan H., Lasseter KC., Mucklow JC., Porras AG. - Studies of the oral bioavailability of alendronate. - Clin. Pharmacol Ther., 58, 288-298, 1995.
10. Siris ES. - A potent new bisphosphonate for Paget's disease of bone. - Am J. Med., 101 (4), 339-340, 1996. (Pubitemid 26397230)
11. Baker D.E. - Alendronate and risedronate: what you need to know about their upper gastrointestinal tract toxicity. - Rev. Gastroenterol Disord., 2 (1), 20-33, 2002. (Pubitemid 34467666)
12. Sharpe M., Noble S., Spencer CM. - Alendronate: an update of its use in osteoporosis. - Drugs, 61 (7), 999-1039, 2001. (Pubitemid 32575400)
13. Schnitzer T., Bone H.G., Crepaldi G., Adami S., McClung M., Kiel D., Felsenberg D., Recker R.R., Tonino R.P., Roux C., Pinchera A., Foldes A.J., Greenspan S.L., Levine M.A., Emkey R., Santora A.C., Kaur A., Thompson D.E., Yates J., Orloff J.J. - Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. - ALD Once-Weekly Study Group. Aging, Milano, 12 (1), 1-12, 2000. (Pubitemid 30136655)
14. Shakweh M., Bravo-Osuna I., Ponchel G. - Comparative in vitro study of oesophageal adhesiveness of different commercial formulations containing alendronate. - Eur. J. Pharm Sci., 31 (5), 262-270, 2007. (Pubitemid 47068937)
15. Miller PD., Schnitzer T., Emkey R., Orwoll E., Rosen C., Ettinger M., Vandormael K., Daifotis A. - Weekly oral alendronic acid in male osteoporosis. - Clin. Drug Investig., 24 (6), 333-341, 2004. (Pubitemid 38858256)
16. Ezra A., Golomb G. - Administration routes and delivery systems of bisphosphonates for the treatment of bone resorption. - Adv. Drug Deliv. Rev., 42 (3), 175-195, 2000. (Pubitemid 30645777)
17. Lin JH., Chen IW., deLuna FA., Hichens M. - Role of calcium in plasma protein binding and renal handling of alendronate in hypo and hypercalcemic rats. - J. Pharmacol Exp. Ther., 267, 670-675, 1993. (Pubitemid 23352522)
18. Lin J.H., Chen I.W., Duggan D.E. - Effects of dose, sex, and age on the disposition of alendronate, a potent antiosteolytic bisphosphonate in rats. - Drug Metab. Dispos., 20, 473-478, 1992.
19. Rossini M., Braga V., Gatti D., Gerardi D., Zamberlan N., Adami S. - Intramuscular clodronate therapy in postmenopausal osteoporosis. - Bone, 24 (2), 125-129, 1999. (Pubitemid 29070804)
20. Valenta C. The use of mucoadhesive polymers in vaginal delivery. - Adv. Drug Deliv. Rev., 57 (11), 1692-1712, 2005. (Pubitemid 41444256)
21. Krishnaiah Y.S., Satyanarayana S., Rama Prasad Y.V., Narasimha Rao S. - Gamma scintigraphic studies on guar gum matrix tablets for colonic drug delivery in healthy human volunteers. - J. Control Release, 55 (2-3), 245-252, 1998. (Pubitemid 28477615)
22. Marvola T., Marvola J., Kanerva H., Ahonen A., Lindevall K., Marvola M. - Neutron activation based gamma scintigraphic evaluation of enteric-coated capsules forlocal treatment in colon. - Int. J. Pharm., 349 (1-2), 24-29, 2008. (Pubitemid 350299683)
23. Asikoglu M., Ozguney I., Ozcan I., Orumlu O., Guneri T., Koseoglu K., Ozkilic H. - The absorption of 99mTc-alendronate given by rectal route in rabbits. - Pharm. Dev. Technol., 13 (3), 213-220, 2008. (Pubitemid 351882239)
24. Lin JH. - Bisphosphanates: a review of their pharmacokinetic properties. - Bone, 18, 75-85, 1996. (Pubitemid 26092586)
25. Wang D., Miller S.C., Sima M., Kopecková P., Kopecek J. - Synthesisand evaluation of water-soluble polymeric bone-targeted drug delivery systems. - Bioconjugate Chem., 14, 853-859, 2003. (Pubitemid 37157997)